Go Deep
Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -21,097 | 4.7 | -3.67 | -2.28 | 341.89 |
| Oct 2026 | -21,110 | 4.7 | -3.68 | -2.28 | 341.81 |
| Oct 2026 | -21,344 | 4.9 | -3.85 | -2.28 | 358.00 |
| Oct 2026 | -20,973 | 4.5 | -3.57 | -2.28 | 331.50 |
| Oct 2026 | -21,055 | 4.6 | -3.63 | -2.28 | 337.55 |
| Oct 2026 | -21,152 | 4.7 | -3.71 | -2.28 | 344.18 |
| Oct 2026 | -21,041 | 4.6 | -3.62 | -2.28 | 335.77 |
| Oct 2026 | -21,069 | 4.6 | -3.65 | -2.28 | 336.98 |
| Oct 2026 | -20,918 | 4.5 | -3.53 | -2.28 | 327.95 |
Ironwood Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 113,041,000.0 | 106,506,000.0 | 47,709,000.0 | 122,060,000.0 |
| Net Profit | 51,291,000.0 | 40,773,000.0 | -2,276,000.0 | 40,080,000.0 |
| EPS | 0.3 | 0.2 | -0.0 | 0.2 |
Ironwood Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 296,151,000.0 | 351,410,000.0 | 442,735,000.0 | 410,596,000.0 | — |
| Net Profit | 24,017,000.0 | 880,000.0 | -1,002,239,000.0 | 175,065,000.0 | — |
| EPS | 0.1 | 0.0 | -6.5 | 1.1 | — |
Ironwood Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 396,901,000.0 | 350,908,000.0 | 471,073,000.0 | 1,100,519,000.0 | — |
| Total Liabilities | 658,736,000.0 | 652,243,000.0 | 817,368,000.0 | 448,141,000.0 | — |
| Total Equity | -261,835,000.0 | -301,335,000.0 | -346,295,000.0 | 652,378,000.0 | — |
Owes vs Owns
Ironwood Pharmaceuticals, Inc. owed $1.57 for every $1 it owned in Jun 2026, up from $0.41 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.57× | 1.66× | 1.86× | 1.74× | 0.41× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Ironwood Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 54.3%Receivables 11.8%Fixed assets (tangible) 3.2%Intangible assets 0.5%Other assets 30.2%
How it's funded — Dec 2025
Short-term debt 30.3%Long-term debt 58.4%Other liabilities 10.8%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 215.5 | 88.6 | 92.2 | 656.2 |
| Receivables | 46.7 | 81.9 | 129.1 | 115.5 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 12.7 | 15.5 | 18.2 | 20.3 |
| Intangible assets | 2.0 | 2.9 | 3.7 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 119.9 | 162.1 | 227.9 | 308.5 |
| Liabilities & equity | ||||
| Short-term debt | 199.7 | 3.2 | 199.6 | 3.1 |
| Long-term debt | 385.0 | 584.0 | 498.3 | 396.3 |
| Payables | 2.9 | 2.1 | 7.8 | 0.5 |
| Other liabilities | 71.2 | 62.9 | 111.7 | 48.3 |
| Shareholders' equity | -261.8 | -301.3 | -346.3 | 652.4 |
| Net tangible assets | -263.9 | -304.2 | -350.0 | 652.4 |
Ironwood Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 127,044,000.0 | 103,549,000.0 | 183,427,000.0 | 273,763,000.0 | — |
| Investing Activities | -34,000.0 | -142,000.0 | -1,026,318,000.0 | -136,000.0 | — |
| Financing Activities | 216,000.0 | -106,970,000.0 | 277,160,000.0 | -237,553,000.0 | — |